Justin van Meeteren1, Simon Maltais1, Shannon M Dunlay1, Nicholas A Haglund2, Mary Beth Davis2, Jennifer Cowger3, Palak Shah4, Keith D Aaronson5, Francis D Pagani5, John M Stulak6. 1. Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. 2. Department of Cardiovascular Surgery, Vanderbilt Heart and Vascular Center, Nashville, Tennessee, USA. 3. Division of Cardiovascular Diseases, St. Vincent's Hospital, Indianapolis, Indiana, USA. 4. Division of Cardiovascular Diseases, Inova Heart and Vascular Institute, Falls Church, Virginia, USA. 5. Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA. 6. Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Electronic address: stulak.john@mayo.edu.
Abstract
BACKGROUND: Earlier studies have demonstrated disparities in patients undergoing left ventricular assist device (LVAD) implantation when stratified according to sex and race. Because very few data exist from large investigations, we reviewed data from the registry of the Mechanical Circulatory Support Research Network. METHODS: Between May 2004 and September 2014, 734 patients underwent primary LVAD implantation at our institutions. Median age at implant was 57 (range 18 to 82) years and there were 577 males (80%). Race included Caucasian (C) in 586 patients (82%), African-American (AA) in 112 (16%), and other (O) in 21 (3%). Between sexes, significant pre-operative differences most commonly included median age at implant (males 60 years, females 57 years), ischemic etiology (53% vs 35%) and mean INTERMACS profile (2.9 vs 2.5). Between races, significant pre-operative differences most commonly included median age at implant (C = 61 vs AA = 51 vs O = 51), New York Heart Association functional class (85% vs 100% vs 92%) and ischemic etiology (55% vs 24% vs 40%). RESULTS: There were no significant differences in survival at 1, 3 or 5 years by sex or race. Similarly, there were no differences in time-related freedom from stroke, drive-line infection, gastrointestinal bleeding or pump thrombus by sex or race. After controlling for differences, neither sex nor race was associated with survival (p = 0.09 and p = 0.18, respectively), stroke (p = 0.28 and p = 0.21), drive-line infection (p = 0.9 and p = 0.92), gastrointestinal bleed (p = 0.48 and p = 0.45) or pump thrombus (p = 0.99 and p = 0.8). CONCLUSIONS: In this large, multi-institutional analysis, although some pre-operative clinical characteristics varied, they did not translate into any significant differences in late survival or complications while on LVAD support.
BACKGROUND: Earlier studies have demonstrated disparities in patients undergoing left ventricular assist device (LVAD) implantation when stratified according to sex and race. Because very few data exist from large investigations, we reviewed data from the registry of the Mechanical Circulatory Support Research Network. METHODS: Between May 2004 and September 2014, 734 patients underwent primary LVAD implantation at our institutions. Median age at implant was 57 (range 18 to 82) years and there were 577 males (80%). Race included Caucasian (C) in 586 patients (82%), African-American (AA) in 112 (16%), and other (O) in 21 (3%). Between sexes, significant pre-operative differences most commonly included median age at implant (males 60 years, females 57 years), ischemic etiology (53% vs 35%) and mean INTERMACS profile (2.9 vs 2.5). Between races, significant pre-operative differences most commonly included median age at implant (C = 61 vs AA = 51 vs O = 51), New York Heart Association functional class (85% vs 100% vs 92%) and ischemic etiology (55% vs 24% vs 40%). RESULTS: There were no significant differences in survival at 1, 3 or 5 years by sex or race. Similarly, there were no differences in time-related freedom from stroke, drive-line infection, gastrointestinal bleeding or pump thrombus by sex or race. After controlling for differences, neither sex nor race was associated with survival (p = 0.09 and p = 0.18, respectively), stroke (p = 0.28 and p = 0.21), drive-line infection (p = 0.9 and p = 0.92), gastrointestinal bleed (p = 0.48 and p = 0.45) or pump thrombus (p = 0.99 and p = 0.8). CONCLUSIONS: In this large, multi-institutional analysis, although some pre-operative clinical characteristics varied, they did not translate into any significant differences in late survival or complications while on LVAD support.
Authors: Manal Alasnag; Alexander G Truesdell; Holli Williams; Sara C Martinez; Syeda Kashfi Qadri; John P Skendelas; William A Jakobleff; Mirvat Alasnag Journal: Curr Atheroscler Rep Date: 2020-04-23 Impact factor: 5.113
Authors: Imad M Hariri; Todd Dardas; Manreet Kanwar; Rebecca Cogswell; Igor Gosev; Ezequiel Molina; Susan L Myers; James K Kirklin; Palak Shah; Francis D Pagani; Jennifer A Cowger Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 10.247
Authors: Silvia Mariani; Tong Li; Karl Bounader; Dietmar Boethig; Alexandra Schöde; Jasmin S Hanke; Jana Michaelis; L Christian Napp; Dominik Berliner; Guenes Dogan; Roberto Lorusso; Axel Haverich; Jan D Schmitto Journal: Ann Cardiothorac Surg Date: 2021-03
Authors: Kelsey Flint; Erin L Chaussee; Kamal Henderson; Khadijah Breathett; Prateeti Khazanie; Jocelyn S Thompson; Colleen K Mcilvennan; Shane J Larue; Daniel D Matlock; Larry A Allen Journal: J Card Fail Date: 2020-12-18 Impact factor: 5.712
Authors: Larry A Allen; Colleen K McIlvennan; Jocelyn S Thompson; Shannon M Dunlay; Shane J LaRue; Eldrin F Lewis; Chetan B Patel; Laura Blue; Diane L Fairclough; Erin C Leister; Russell E Glasgow; Joseph C Cleveland; Clifford Phillips; Vicie Baldridge; Mary Norine Walsh; Daniel D Matlock Journal: JAMA Intern Med Date: 2018-04-01 Impact factor: 21.873